Trials / Completed
CompletedNCT01612715
Analysis of Fel d 1-specific T Cells After Airway Allergen Challenge in Asthma
Analysis of Fel d 1-specific T Cells After Airway Allergen Challenge in Asthma:Frequency and Phenotype and Trafficking of Cat Allergen-specific T-cells in Blood, Bone Marrow and Bronchoalveolar Lavage Fluid (BALF) Following Segmental Allergen Challenge in Allergic Asthma.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 38 (actual)
- Sponsor
- Hamilton Health Sciences Corporation · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Cat allergies are a major trigger of asthma. Therapies are being developed to control the allergic response to cats. We are interested in measuring a type of white blood cell which is linked to cat allergies, which will help us understand how to use new therapies in people who suffer from cat allergies and asthma. We will study cat-allergic individuals with stable, mild asthma who will be exposed to cat allergens. We will measure various white blood cells, including the cells that are linked to cat allergies, to determine whether the number of these cells changes following cat exposure. These cells will be measured from the blood and bone marrow by removing samples using a needle. These cells will also be measured from the lungs by inserting a bronchoscope into the airways and drawing up fluid containing cells. This study will improve our understanding of the harmful versus protective role of these cat-specific cells, and will allow for development of better drugs for treatment of asthma triggered by cat exposure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Segmental Allergen Challenge | segmental allergen challenge |
Timeline
- Start date
- 2014-01-29
- Primary completion
- 2018-03-22
- Completion
- 2018-03-22
- First posted
- 2012-06-06
- Last updated
- 2019-07-30
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01612715. Inclusion in this directory is not an endorsement.